logo-loader

Silence Therapeutics 'honour-bound' to attack and defend their patents - CEO Ali Mortazavi

Published: 10:20 16 May 2017 BST

Ali Mortazavi, chief executive of Silence Therapeutics PLC (LON:SLN) breaks down the detail to Proactive's Andrew Scott on why they're seeking payments from a number of developers for drugs already in late-stage development.

Mortazavi adds that they've also filed for more patent protection for their RNA therapeutics/gene silencing technology.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

56 minutes ago